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This case describes the increased anticoagulation eﬀect associated with the use of high-dose ketoconazole. A 59-year-old man
treated with warfarin for aortic valve replacement was prescribed high-dose ketoconazole and hydrocortisone for the treatment
of prostate cancer. Despite lowering the warfarin dosage by 35% during the start of high dose ketoconazole, an additional
dose reduction was required subsequently when the INR rose from 2.62 to 3.82 within nine days. After a total dose reduction
of 43%, the INR returned to therapeutic range within two weeks. The Naranjo probability scale revealed a probable adverse
reaction of increased anticoagulant eﬀect associated with high dose ketoconazole. Due to the inhibition of warfarin metabolism
by ketoconazole, patients taking high dose ketoconazole concomitantly with warfarin may need their warfarin dosage reduced by
more than is currently recommended, as well as receive more frequent INR monitoring to avoid over anticoagulation.
Copyright © 2009 C. A. Jackevicius and M. N. Ton. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Prostate cancer is the most common male malignancy,
ranking third in cancer incidence worldwide and sixth in
cancer mortality among men [1]. In advanced prostate
cancer, androgen deprivation (AD) is the primary ther-
apeutic approach. Despite initial response rates of 80%–
90% to AD therapy, nearly all men experience progression
after 18–24 months [2]. Alternatives to AD are secondary
hormonal interventions such as high-dose ketoconazole
(HDK), aminoglutethimide, or diethylstilbestrol [2, 3].
Ketoconazole is an imidazole derivative antifungal, which
also has testosterone lowering eﬀects by decreasing testicular
and adrenal production of androgens by inhibiting adrenal
and gonadal steroid syntheses. At high-doses, ketoconazole
inhibits the cholesterol side chain cleavage, P450c17, C17,
20 lyase, 3β-hydroxysteroid dehydrogenase, and P450c11
enzymes required for steroid hormone synthesis [4, 5].
Ketoconazole inhibitory eﬀects on steroid biosynthesis are
seen only at high-doses [4, 5]. In addition, ketoconazole has
been shown to have direct cell killing action on prostate
cancercells[6].Asaresultofthesemechanisms,HDKisnow
being used for men with hormone refractory prostate cancer
(HRPC).
As an antifungal, ketoconazole is dosed at 200mg daily,
however,forHRPCtherapy;dosesof200–400mgthreetimes
a day are used to produce castrate levels of testosterone
w i t h i n2 4h o u r s[ 7]. Since ketoconazole is a potent inhibitor
of cytochrome P450 isoenzymes in the liver, it can increase
concentrationsandpotentiate theeﬀectsofsomedrugs,such
as cyclosporine, phenytoin, oral hypoglycemics, and oral
anticoagulants [7]. Other antifungals, including ﬂuconazole,
voriconazole, and miconazole, have highly probable reports
of drug interactions with warfarin [8].2 Case Reports in Medicine
2. Case Presentation
A 59-year-old man had been treated with warfarin with
an INR goal of 3.0 for the last ﬁve years after receiving
a mechanical aortic valve replacement. His past medi-
cal history includes diabetes mellitus type 2, hyperlipi-
demia, hypertension, depression, chronic obstructive pul-
monary disease, gastroesophageal reﬂux disease, osteoarthri-
tis, and prostate cancer. His medications included albuterol
and ipratropium inhaler, benztropine, calcium/vitamin D,
guaifenesin/dexamethorphan, docusate, furosemide, gly-
buride, goserelin, hydrocodone/acetaminophen, lisinopril,
lorazepam, metoprolol tartrate, nitroglycerin sublingual,
omeprazole, potassium chloride, prochlorperazine, quetiap-
ine, simvastatin, terazosin, and trazodone. His INR had been
therapeutic in the past two months on a usual weekly dose of
52.5mg. His only other elevated INR prior to this period was
when antibiotics were started for an acute infection, and his
INR increased from 3.03 to 4.27.
In March 2006, the patient was prescribed ketoconazole
400mg three times a day and hydrocortisone 10mg daily
by his urologist for treatment of prostate cancer. As part
of the pharmacist-managed anticoagulation program, the
pharmacist decreased the warfarin weekly dose by 35% to
avoid overanticoagulation. This dose adjustment was based
on the recommendation from standard clinical references
to reduce the warfarin dose by one-third [9]. The patient
returned to the anticoagulation clinic on days 3, 9, and 20
aftertheinitiationofHDK.HisINRreadingswere2.61,3.82,
and 3.16, respectively. During these three visits, he denied
bleeding or dietary and medication changes. Due to the
increase in INR on day 9 with no other reasons contributing
to the INR elevation, the warfarin dosage was further
decreased to 30mg per week, resulting in a total warfarin
dose reduction of 43% since ketoconazole initiation. On day
20, his INR was therapeutic at 3.16 and warfarin control was
reestablished within the therapeutic goal thereafter.
3. Discussion
In this case, despite lowering the warfarin dosage by 35%
during the start of HDK, an additional dose reduction was
required when the INR increased to 3.82 within nine days.
A total dose reduction of 43% was required to bring the
anticoagulanteﬀecttotherapeuticgoalandtoavoidbleeding
complications. No new medications besides ketoconazole
and hydrocortisone were started during this period of time.
The medications listed previously were chronic medica-
tions that the patient had been taking for years, except
for calcium/vitamin D, guaifenesin/dexamethorphan, and
glyburide which were started within two months prior to the
initiation of ketoconazole and hydrocortisone. Among the
concurrentmedicationswithwarfarin,onlyomeprazole,gly-
buride, and ketoconazole show an enhanced anticoagulation
eﬀect [9]. The drug interactions between omeprazole and
warfarin as well as glyburide and warfarin had already been
accounted for prior to the start of HDK, thus implicating
ketoconazole in the potentiation of the warfarin eﬀect.
The Naranjo, the modiﬁed Naranjo adverse drug reaction
probability scales, and the Holbrook criteria all revealed
a probable adverse reaction of an increased anticoagulant
eﬀect associated with HDK [8, 10, 11].
To our knowledge, this is the ﬁrst report of the poten-
tiation of oral anticoagulants by HDK. The mechanism of
the drug interaction is most likely due to the inhibition of
warfarin metabolism. Ketoconazole is a potent inhibitor of
cytochrome P450 1A2 and 3A4, with moderate inhibitory
eﬀect on isoenzymes 2A6, 2C9, 2C19, and 2D6 [12, 13]. As
warfarinisasubstrateforseveralisoenzymes(CYP1A2,2C9,
2C19, 3A4) that are inhibited by ketoconazole, inhibition of
these isoenzymes may enhance the warfarin anticoagulant
eﬀect [13].
While clinicians may readily acknowledge the interaction
between ketoconazole and warfarin, supporting data are
sparse. In the widely cited evidence-based overview of
warfarindruginteractions,Holbrookandcolleaguesindicate
that ketoconazole has no eﬀect on warfarin at the probable
level, based on a pharmacokinetic study assessing two
patients receiving concurrent warfarin and ketoconazole
[8, 14]. Only one case report has been published demon-
strating warfarin potentiation with low-dose ketoconazole
(200mg/day). This report suggested more frequent INR
monitoring and reduction of the warfarin dosage by one-
third [15]. Current drug interaction references cite this one
report to guide dosage adjustment for this interaction. We
provide the second case report and show that with the use of
HDK, a dose adjustment of one-third may not be adequate.
In our case, a total dose reduction of 43% was required to
bring the INR to therapeutic levels. In light of our case, for
patients taking high-dose ketoconazole concomitantly with
warfarin, it may be prudent to consider a warfarin dosage
reduction of more than 35%, in conjunction with more
frequent INR monitoring.
4. Conclusion
The use of HDK therapy for hormone refractory prostate
cancer has increased. Clinicians must be cognizant and
use caution when HDK is used with warfarin as it can
greatly potentiate the anticoagulation eﬀect, leading to
an increased risk of bleeding. This drug-drug interaction
may be minimized by more frequent INR monitoring and
considering reducing the warfarin dosage by more than
the currently recommended 35% in order to achieve the
therapeutic goal and to avoid overanticoagulation.
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